Back AAAS EurekAlert (18 Dec 2023) 'Toronto study identifies new concepts for GLP-1 action in the brain, the 2023 Science magazine breakthrough of the year'
Chu, C., Tsuprykov, O., Chen, X., Elitok, S., Krmer, B
They ensure side effects are kept to a minimum
All of these GLP-1 effects (Figure 2) are potentially beneficial for patients with T2D, and have been sought exploited clinically with the development of GLP-1R agonists
Transcranial focused ultrasound (FUS) is a noninvasive method used to modulate neural activity in the brain 50,51
In October 2024, Amneal Pharma invested Rs 1,600 crore in Gujarat to manufacture GLP-1 drugs